JP6127063B2 - 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用 - Google Patents

中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用 Download PDF

Info

Publication number
JP6127063B2
JP6127063B2 JP2014548078A JP2014548078A JP6127063B2 JP 6127063 B2 JP6127063 B2 JP 6127063B2 JP 2014548078 A JP2014548078 A JP 2014548078A JP 2014548078 A JP2014548078 A JP 2014548078A JP 6127063 B2 JP6127063 B2 JP 6127063B2
Authority
JP
Japan
Prior art keywords
edema
brain
inhibitor
pharmaceutical composition
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014548078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502389A (ja
JP2015502389A5 (enExample
Inventor
クリストフ・クラインシュニッツ
マルク・ノルテ
グイド・シュトール
ゲルハルト・ディックナイト
シュテファン・シュルテ
ベルンハルト・ニーズヴァント
インゴ・プラークスト
Original Assignee
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー filed Critical ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Publication of JP2015502389A publication Critical patent/JP2015502389A/ja
Publication of JP2015502389A5 publication Critical patent/JP2015502389A5/ja
Application granted granted Critical
Publication of JP6127063B2 publication Critical patent/JP6127063B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014548078A 2011-12-22 2012-12-21 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用 Active JP6127063B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11195254.5 2011-12-22
EP11195254 2011-12-22
US201261587371P 2012-01-17 2012-01-17
US61/587,371 2012-01-17
PCT/EP2012/076691 WO2013093027A1 (en) 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system

Publications (3)

Publication Number Publication Date
JP2015502389A JP2015502389A (ja) 2015-01-22
JP2015502389A5 JP2015502389A5 (enExample) 2016-02-12
JP6127063B2 true JP6127063B2 (ja) 2017-05-10

Family

ID=48667767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548078A Active JP6127063B2 (ja) 2011-12-22 2012-12-21 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用

Country Status (10)

Country Link
US (1) US9452203B2 (enExample)
EP (1) EP2793935B1 (enExample)
JP (1) JP6127063B2 (enExample)
KR (1) KR102022231B1 (enExample)
CN (1) CN104080474B (enExample)
AU (1) AU2012318275B2 (enExample)
CA (1) CA2858984C (enExample)
DK (1) DK2793935T3 (enExample)
ES (1) ES2587863T3 (enExample)
WO (1) WO2013093027A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
ME02865B (me) 2013-03-15 2018-04-20 Shire Viropharma Inc C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (en) * 2014-11-21 2016-05-26 Kurt Baekgaard Osther Recombinant c1 esterase inhibitor and use thereof
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
CN108463243B (zh) 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
MA71249A (fr) 2022-06-24 2025-04-30 Bioverativ Usa Inc. Méthodes de traitement de maladies médiées par complément

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4227762A1 (de) 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
JP3941174B2 (ja) 1996-08-26 2007-07-04 富士ゼロックス株式会社 複合材料及びその製造方法
WO2001019392A1 (en) 1999-09-16 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US8071532B2 (en) * 2005-12-21 2011-12-06 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
PT2380587T (pt) * 2005-12-21 2018-01-19 Pharming Intellectual Property B V Resumo

Also Published As

Publication number Publication date
CN104080474B (zh) 2016-04-27
CA2858984C (en) 2021-01-05
KR102022231B1 (ko) 2019-09-19
DK2793935T3 (en) 2016-09-05
EP2793935A1 (en) 2014-10-29
US9452203B2 (en) 2016-09-27
US20140371425A1 (en) 2014-12-18
CN104080474A (zh) 2014-10-01
CA2858984A1 (en) 2013-06-27
ES2587863T3 (es) 2016-10-27
AU2012318275A1 (en) 2013-07-11
AU2012318275B2 (en) 2016-05-19
EP2793935B1 (en) 2016-05-25
WO2013093027A1 (en) 2013-06-27
JP2015502389A (ja) 2015-01-22
HK1201729A1 (zh) 2015-09-11
KR20140107567A (ko) 2014-09-04

Similar Documents

Publication Publication Date Title
US9452203B2 (en) Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
Göb et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation
Kraft et al. The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood–brain-barrier damage, inflammation and thrombosis
Diringer et al. Aneurysmal subarachnoid hemorrhage: strategies for preventing vasospasm in the intensive care unit
US20160250189A1 (en) Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
KR101956585B1 (ko) 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법
JP2015509984A (ja) 子癇前症の治療におけるアンチトロンビンの使用
CA2879763C (en) The use of antithrombin in extracorporeal membrane oxygenation
US20240425863A1 (en) Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity
Edvinsson et al. Late cerebral ischaemia after subarachnoid haemorrhage: is cerebrovascular receptor upregulation the mechanism behind?
Wang et al. Protective and detrimental effects of neuroectodermal cell–derived tissue factor in mouse models of stroke
US7375076B2 (en) Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
JP2006510620A (ja) 心筋梗塞の治療方法
HK1201729B (en) Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
JP6289511B2 (ja) 羊水塞栓の治療剤
S Hernandes et al. Hernandes et al., 2018. pdf
Tamanna et al. ACE2: A key modulator of RAS and pregnancy
Elkhrbash The role of angiotensin AT1 and AT2 receptors in the development of apoptosis and inflammation following experimental myocardial infarction
KR20250175983A (ko) 모야모야병 예후 예측용 HIF1a 바이오마커 및 이의 용도
KR20250175982A (ko) 모야모야병 예후 예측용 bnip3l 바이오마커 및 이의 용도
Song et al. Up-regulation of TGF-β via the activation of extracellular signal-regulated kinase 1 and 2 induced by prorenin in human renal mesangial cells
KR20250175987A (ko) 자가포식 및 미토파지 바이오마커를 이용한 모야모야병의 예후 예측을 위한 정보제공방법
Nagata et al. Systemically administered thrombin inhibitors can prevent neointimal formation and cerebral vasospasm: the possible role of thrombin and PDGF-BB in vascular pathogeneses
Lameire Pathophysiology of acute renal failure in sepsis
Fernández et al. Time-dependent dual effect of NLRP3 inflammasome in brain ischemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170410

R150 Certificate of patent or registration of utility model

Ref document number: 6127063

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250